Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Awtar Krishan

Showing results (31-40 of 40) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 40 results.
American Journal of Clinical Oncology|February 8, 2006
Influence of number of CAG repeats on local control in the RTOG 86-10 protocolMay Abdel-Wahab, Brian A Berkey, Awtar Krishan, et al.
Cell Cycle (Georgetown, Tex.)|October 26, 2012
GHRH antagonist when combined with cytotoxic agents induces S-phase arrest and additive growth inhibition of human colon cancerFerenc G Rick, Stephan Seitz, Andrew V Schally, et al.
Cell Cycle (Georgetown, Tex.)|December 9, 2014
Novel GHRH antagonists suppress the growth of human malignant melanoma by restoring nuclear p27 functionLuca Szalontay, Andrew V Schally, Petra Popovics, et al.
International Journal of Radiation Oncology, Biology, Physics|October 9, 2007
Are increased tumor aneuploidy and heightened cell proliferation along with heterogeneity associated with patient outcome for carcinomas of the uterine cervix? A combined analysis of subjects treated in RTOG 9001 and a single-institution trialAaron H Wolfson, Kathryn Winter, William Crook, et al.
Cancer Letters|February 17, 2010
Targeted cytotoxic somatostatin analog AN-162 inhibits growth of human colon carcinomas and increases sensitivity of doxorubicin resistant murine leukemia cellsFlorian Hohla, Stefan Buchholz, Andrew V Schally, et al.
Cancer Chemotherapy and Pharmacology|March 24, 2006
Efficacy of 2-halogen substituted D-glucose analogs in blocking glycolysis and killing "hypoxic tumor cells"Theodore J Lampidis, Metin Kurtoglu, Johnathan C Maher, et al.
Cell Cycle (Georgetown, Tex.)|July 4, 2012
Combination of gastrin-releasing peptide antagonist with cytotoxic agents produces synergistic inhibition of growth of human experimental colon cancersFerenc G Rick, Stefan Buchholz, Andrew V Schally, et al.
International Journal of Oncology|September 3, 2009
Triple-negative breast cancers express receptors for luteinizing hormone-releasing hormone (LHRH) and respond to LHRH antagonist cetrorelix with growth inhibitionStefan Buchholz, Stephan Seitz, Andrew V Schally, et al.
Cell Cycle (Georgetown, Tex.)|September 17, 2009
GHRH antagonist causes DNA damage leading to p21 mediated cell cycle arrest and apoptosis in human colon cancer cellsFlorian Hohla, Stefan Buchholz, Andrew V Schally, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 30, 2013
Shrinkage of experimental benign prostatic hyperplasia and reduction of prostatic cell volume by a gastrin-releasing peptide antagonistFerenc G Rick, Andrew Abi-Chaker, Luca Szalontay, et al.
Pageof 4

Showing results (31-40 of 40) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 40 results.
American Journal of Clinical Oncology|February 8, 2006
Influence of number of CAG repeats on local control in the RTOG 86-10 protocolMay Abdel-Wahab, Brian A Berkey, Awtar Krishan, et al.
Cell Cycle (Georgetown, Tex.)|October 26, 2012
GHRH antagonist when combined with cytotoxic agents induces S-phase arrest and additive growth inhibition of human colon cancerFerenc G Rick, Stephan Seitz, Andrew V Schally, et al.
Cell Cycle (Georgetown, Tex.)|December 9, 2014
Novel GHRH antagonists suppress the growth of human malignant melanoma by restoring nuclear p27 functionLuca Szalontay, Andrew V Schally, Petra Popovics, et al.
International Journal of Radiation Oncology, Biology, Physics|October 9, 2007
Are increased tumor aneuploidy and heightened cell proliferation along with heterogeneity associated with patient outcome for carcinomas of the uterine cervix? A combined analysis of subjects treated in RTOG 9001 and a single-institution trialAaron H Wolfson, Kathryn Winter, William Crook, et al.
Cancer Letters|February 17, 2010
Targeted cytotoxic somatostatin analog AN-162 inhibits growth of human colon carcinomas and increases sensitivity of doxorubicin resistant murine leukemia cellsFlorian Hohla, Stefan Buchholz, Andrew V Schally, et al.
Cancer Chemotherapy and Pharmacology|March 24, 2006
Efficacy of 2-halogen substituted D-glucose analogs in blocking glycolysis and killing "hypoxic tumor cells"Theodore J Lampidis, Metin Kurtoglu, Johnathan C Maher, et al.
Cell Cycle (Georgetown, Tex.)|July 4, 2012
Combination of gastrin-releasing peptide antagonist with cytotoxic agents produces synergistic inhibition of growth of human experimental colon cancersFerenc G Rick, Stefan Buchholz, Andrew V Schally, et al.
International Journal of Oncology|September 3, 2009
Triple-negative breast cancers express receptors for luteinizing hormone-releasing hormone (LHRH) and respond to LHRH antagonist cetrorelix with growth inhibitionStefan Buchholz, Stephan Seitz, Andrew V Schally, et al.
Cell Cycle (Georgetown, Tex.)|September 17, 2009
GHRH antagonist causes DNA damage leading to p21 mediated cell cycle arrest and apoptosis in human colon cancer cellsFlorian Hohla, Stefan Buchholz, Andrew V Schally, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 30, 2013
Shrinkage of experimental benign prostatic hyperplasia and reduction of prostatic cell volume by a gastrin-releasing peptide antagonistFerenc G Rick, Andrew Abi-Chaker, Luca Szalontay, et al.
Pageof 4